{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nutex Health, Inc.
Is Nutex Health, Inc. overvalued or undervalued?
As of October 17, 2025, Nutex Health, Inc. has improved its valuation outlook to very attractive, showing strong undervaluation with a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and a remarkable ROCE of 128.63%, alongside impressive stock performance with a year-to-date return of 199.26% and a three-year return of 10,965.93%.
Is Nutex Health, Inc. overvalued or undervalued?
As of October 17, 2025, Nutex Health, Inc. is rated as very attractive due to its low P/E ratio of 5, an EV to EBITDA ratio of 2.82, a high ROCE of 128.63%, and a year-to-date stock return of 199.26%, significantly outperforming the S&P 500's 13.30%.
Is Nutex Health, Inc. technically bullish or bearish?
As of June 9, 2025, Nutex Health, Inc. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 significantly year-to-date with a return of 193.34% compared to 12.22%.
Is Nutex Health, Inc. overvalued or undervalued?
As of July 7, 2025, Nutex Health, Inc. has shifted from an attractive to a very attractive valuation grade, showing strong undervaluation with a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and a ROCE of 128.63%, significantly outperforming peers and the S&P 500 with a 273.93% return over the year.
Nutex Health Achieves 279.75% Growth, Establishing It as a Multibagger in Biotechnology Sector
Nutex Health, Inc. has recently undergone a revision in its score, reflecting its impressive performance in the Pharmaceuticals & Biotechnology sector. The company has achieved significant growth over the past year, outpacing the S&P 500, while maintaining strong financial health and operational efficiency, attracting increased institutional interest.
Nutex Health's Valuation Upgrade Reflects Strong Financial Performance and Market Position
Nutex Health, Inc. has recently experienced a significant change in its valuation grade, reflecting its strong market position. Key financial metrics include a P/E ratio of 5, a robust ROCE of 128.63%, and impressive net sales growth of 221.06%, indicating effective operational performance and financial health.
Is Nutex Health, Inc. overvalued or undervalued?
As of June 4, 2025, Nutex Health, Inc. is considered very attractive and undervalued with a P/E ratio of 5, strong financial ratios including a ROCE of 128.63% and ROE of 76.34%, and a year-to-date return of 268.73%, making it a compelling investment opportunity despite a recent 12.65% decline in stock performance.
Is Nutex Health, Inc. technically bullish or bearish?
As of June 9, 2025, Nutex Health, Inc. shows a mildly bullish trend, supported by daily moving averages and monthly Bollinger Bands, despite some short-term caution indicated by weekly MACD and KST.
What does Nutex Health, Inc. do?
Nutex Health, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $212 million and a net profit of $44 million. Key metrics include a P/E ratio of 5.00 and a return on equity of 76.34%.
How big is Nutex Health, Inc.?
As of Jun 18, Nutex Health, Inc. has a market capitalization of 641.62 million and net sales of 624.28 million with a net profit of 140.03 million over the latest four quarters. Shareholder's funds are 146.34 million, and total assets amount to 669.90 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
